Skip to main content
Top
Published in: memo - Magazine of European Medical Oncology 4/2020

01-12-2020 | Solid Tumor | consensus report

Position statement of the Austrian Society for Hematology and Medical Oncology on the use of molecular diagnostics in solid tumors

Authors: Gerald Prager, Armin Gerger, Gerald Höfler, Gerald Webersinke, Holger Rumpold, Thomas Winder, Rupert Bartsch, Matthias Preusser, Wolfgang Eisterer

Published in: memo - Magazine of European Medical Oncology | Issue 4/2020

Login to get access

Summary

The Austrian Society for Hematology and Medical Oncology (OeGHO) aimed to define a clear position on the importance of molecular diagnostics in solid tumors. This position covers the following four points: the indication for the assessment of a molecular profile has to be given by the treating medical oncologist depending on the course of the patient’s disease; the requirement that the molecular profile might lead to a therapeutic intervention in the individual patient; quality control of the molecular analysis through proficiency testing and/or accreditation of the method used; and adherence to patient’s data safety according to data protection regulation. The present position paper does not cover the topic of germline mutations and other assessments in human genetics. Due to the fact that clinically relevant information on germline mutations may appear during the diagnostic processing we strongly recommend thorough patient education and documentation of patient consent.
Metadata
Title
Position statement of the Austrian Society for Hematology and Medical Oncology on the use of molecular diagnostics in solid tumors
Authors
Gerald Prager
Armin Gerger
Gerald Höfler
Gerald Webersinke
Holger Rumpold
Thomas Winder
Rupert Bartsch
Matthias Preusser
Wolfgang Eisterer
Publication date
01-12-2020
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 4/2020
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-020-00662-5

Other articles of this Issue 4/2020

memo - Magazine of European Medical Oncology 4/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine